Medicine directory

Oncology medicines, treatment questions, and official source links.

Use these pages to prepare for a doctor conversation or second opinion. They are educational and do not replace the prescribing information or your oncology team.

Search medicines

Start with high-value cancer medicines and expand by specialty.

Search by generic name, brand name, class, biomarker, or topic.

CD20-directed monoclonal antibody

Rituximab

Rituxan

Used in selected blood cancers and immune conditions depending on diagnosis and treatment plan.

EGFR tyrosine kinase inhibitor

Osimertinib

Tagrisso

Used in certain EGFR-mutated non-small cell lung cancer settings.

HER2-directed antibody-drug conjugate

Fam-trastuzumab deruxtecan

Enhertu

Used in selected HER2-expressing cancers depending on diagnosis, prior therapy, and biomarker status.

HER2-directed monoclonal antibody

Trastuzumab

Herceptin

Used in HER2-positive cancers in specific treatment settings.

PARP inhibitor

Olaparib

Lynparza

Used in selected cancers with DNA repair pathway relevance depending on biomarker and treatment setting.

PD-1 inhibitor immunotherapy

Nivolumab

Opdivo

Used in several solid tumors and blood cancers depending on cancer type, stage, and prior treatment.

PD-1 inhibitor immunotherapy

Pembrolizumab

Keytruda

Used across multiple cancer types depending on diagnosis, stage, biomarkers, and treatment setting.

PD-L1 inhibitor immunotherapy

Atezolizumab

Tecentriq

Used in selected cancers where immunotherapy is part of an approved treatment pathway.

Platinum chemotherapy

Carboplatin

Paraplatin

Used in many cancer treatment plans, often with other chemotherapy, immunotherapy, or targeted therapy.

Taxane chemotherapy

Paclitaxel

Taxol

Used in many cancer treatment plans, often in combination with other medicines.

Trop-2-directed antibody-drug conjugate

Sacituzumab govitecan

Trodelvy

Used in selected advanced cancers after specific prior treatments.

Tyrosine kinase inhibitor

Imatinib

Gleevec

Used in selected blood cancers and tumors where the relevant molecular target is present.